Superworth

Neurocrine Biosciences price to free cash flow NBIX

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Nov 2, 2026
17.0×
8-year median
35.5×
Against its 8-year history
2nd
percentile: 0 is its lowest day, 100 its highest
8-year range
15.8× to 214×
Peer median
25.2×

Neurocrine Biosciences' price to free cash flow is 17.0× as of Nov 2, 2026.

That is below its 8-year median of 35.5×, lower than on 98% of days in the last 8 years.

Over that time it ranged from 15.8× in Oct 2026 to 214× in Nov 2019.

The median for 10 biotech stocks of a similar size is 25.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far17.0×15.8×23.7×
202524.4×16.3×34.9×
202432.1×22.0×38.9×
202333.7×27.4×66.8×
202264.9×22.1×92.8×
202125.1×23.5×49.3×
202038.4×25.6×126×
2019122×91.2×214×
201888.3×88.3×136×

Against its peers

Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.

CompanyPrice to free cash flow
NBIXNeurocrine Biosciences17.0×
HALOHalozyme Therapeutics18.2×
EXELExelixis14.8×
TECHBIO-TECHNE43.3×
ALNYAlnylam Pharmaceuticals26.7×
RGENRepligen87.2×
INCYIncyte12.7×
KRYSKrystal Biotech34.0×
UTHRUnited Therapeutics23.7×
ONCBeOne Medicines30.2×
ADMAAdma Biologics21.3×
Peer median25.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Neurocrine Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.